---
document_datetime: 2025-01-14 11:50:02
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/plegridy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: plegridy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 12.30137
conversion_datetime: 2025-12-22 21:51:32.190395
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Plegridy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0079               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/01/2025                          |                                             | PL                               |           |
| IA/0077/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of     | 08/10/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                       |            |     |     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| IB/0076 | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                     | 29/04/2024 | n/a |     |
| IB/0075 | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 06/11/2023 | n/a |     |
| IB/0073 | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                       | 08/09/2023 | n/a |     |
| II/0070 | Submission of the final report from study 105MS401. The objective of this study was to determine the incidence of serious adverse events (SAEs) in patients with relapsing forms of MS in routine clinical practice and to assess the overall long-term clinical effectiveness of peginterferon beta-1a in patients with relapsing forms of MS in routine clinical practice. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 31/08/2023 | n/a | N/A |
| IB/0072 | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                        | 18/08/2023 | n/a |     |

<div style=\"page-break-after: always\"></div>

| IA/0074   | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                       | 10/08/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0071/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                      | 07/08/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0068   | Update of section 4.6 of the SmPC in order to update the information relating to secretion in human milk based on the results from study US-PEG-15-10936, a prospective, open label, post marketing study that measured Plegridy concentrations in breast milk in 6 lactating patients with Multiple Sclerosis. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 30/03/2023   | 19/03/2024 | SmPC and PL | The SmPC section 4.6 has been updated regarding breast- feeding since information available overall suggests that levels of interferon beta-1a/peginterferon beta-1a excreted in human milk are negligible and no harmful effects on the breastfed newborn/infant are anticipated. The PL has been updated accordingly. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IA/0069             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                    | 20/01/2023   | n/a        |                 |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| II/0067             | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                           | 07/07/2022   | n/a        |                 |                                   |
| PSUSA/10275 /202107 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                           | 10/02/2022   | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0064             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                    | 21/10/2021   | n/a        |                 |                                   |
| IA/0065             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                           | 11/10/2021   | n/a        |                 |                                   |
| IA/0063             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                              | 25/03/2021   | n/a        |                 |                                   |
| IAIN/0062/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 11/02/2021   | 04/02/2022 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |                        |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10275 /202007 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                                                                                                                                                                   | 11/02/2021 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0061             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                  | 08/02/2021 | n/a        |                        |                                   |
| X/0056              | Annex I_2.(e) Change or addition of a new route of administration                                                                                                                                                                                                                                                                                                                                     | 15/10/2020 | 14/12/2020 | SmPC, Labelling and PL |                                   |
| IA/0060/G           | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                      | 09/12/2020 | n/a        |                        |                                   |
| N/0058              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                      | 19/08/2020 | 24/09/2020 | PL                     |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0057             | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/05/2020   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10275 /201907 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 13/02/2020   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0052/G           | This was an application for a group of variations. To update sections 4.3 and 4.6 of the SmPC in order to remove the contraindication on the initiation of treatment in pregnancy and to update the recommendations on use in pregnancy and breastfeeding following the completion of the European IFN Beta Pregnancy Registry (8th Annual and final report) and the Final CSR of the register- based study in the Nordic countries (EUPAS13054). The MAH took the opportunity to add information about traceability in section 4.4 of the SmPC. The Package leaflet has been updated accordingly. This submission fulfils MEA 8.2 and 002. The RMP has been updated (ver 4.3) to include changes to the safety specification related to Pregnancy missing information status, in light of the new safety information received, as well as updates to other key sections of the RMP, adapting to the requirements of the GVP Module 5 revision 2 guidelines. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 19/09/2019   | 24/09/2020 | SmPC and PL | The SmPC section 4.3 has been updated to remove the contraindication 'initiation of treatment in pregnancy'. The SmPC section 4.6 has been updated as follows: Pregnancy A large amount of data (more than 1000 pregnancy outcomes) from registries and post-marketing experience indicates no increased risk of major congenital anomalies after pre-conception exposure to interferon beta or such exposure during the first trimester of pregnancy. However, the duration of exposure during the first trimester is uncertain, because data were collected when interferon beta use was contraindicated during pregnancy, and treatment likely interrupted when pregnancy was detected and/or confirmed. Experience with exposure during the second and third trimester is very limited. Based on animal data (see section 5.3), there is a possibly increased risk for spontaneous abortion. The risk of spontaneous abortions in pregnant women exposed to interferon beta cannot adequately be evaluated based on the currently available data, but the data do not suggest an |

<div style=\"page-break-after: always\"></div>

|                     | data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        | increased risk so far. If clinically needed, the use of Plegridy may be considered during pregnancy. Breast-feeding It is not known whether peginferferon beta-1a is secreted in human milk. Limited information available on the transfer of interferon beta-1a into breast milk, together with the chemical / physiological characteristics of interferon beta, suggests that levels of interferon beta-1a excreted in human milk are negligible. No harmful effects on the breastfed newborn/infant are anticipated. Plegridy can be used during breast-feeding.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0054             | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation        | 30/04/2019 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| R/0051              | Renewal of the marketing authorisation.                                                                                  | 31/01/2019 | 25/03/2019 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Plegridy in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                |
| PSUSA/10275 /201807 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                      | 14/02/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IB/0053/G   | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material   | 13/02/2019   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0046     | Update of sections 4.4 and 4.8 of the SmPC in order to add new warning and safety information about anaphylaxis. RMP version 3.3 was also approved. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                     | 04/10/2018   | 25/03/2019 | SmPC | Review of available evidence supports the possibility of a causal relationship between use of peginterferon beta-1a and anaphylactic reaction. Sections 4.4 and 4.8 of the SmPC were updated to include information on anaphylaxis. The SmPC section 4.4 has been updated to include reference to cases of anaphylaxis, to read as follows: Serious hypersensitivity reactions including cases of anaphylaxis have been reported as a rare complication of treatment with interferon beta, including Plegridy. Patients should be advised to discontinue Plegridy and seek immediate medical care if they experience signs and symptoms of anaphylaxis or severe hypersensitivity. Treatment with Plegridy should not be restarted. Section 4.8 of the SmPC, under 'Hypersensitivity reactions' now mentions that in post marketing experience, serious hypersensitivity events including cases of anaphylaxis have |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                               |            |            |                        | been reported (with frequency not known) following Plegridy administration.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------|
| IB/0048 | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                         | 24/08/2018 | n/a        |                        |                                                                               |
| T/0049  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                           | 03/07/2018 | 19/07/2018 | SmPC, Labelling and PL |                                                                               |
| IB/0047 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                        | 14/06/2018 | n/a        |                        |                                                                               |
| N/0045  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                              | 17/04/2018 | 19/07/2018 | Labelling and PL       |                                                                               |
| IB/0044 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                 | 08/03/2018 | n/a        |                        |                                                                               |
| II/0040 | To add an alternate pre-filled syringe (Neopak). The componentsÂ´ materials of the finished product container closure system of the existing pre-filled syringe (Hypak) and the new pre-filled syringe are identical. B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is | 22/02/2018 | n/a        |                        |                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | an integrated part of the primary packaging                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10275 /201707 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                                                                                                      | 08/02/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| IB/0043             | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                               | 10/01/2018 | n/a        |             |                                                                                                                                            |
| IB/0042             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                  | 06/12/2017 | n/a        |             |                                                                                                                                            |
| IA/0041             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                            | 17/11/2017 | n/a        |             |                                                                                                                                            |
| PSUSA/10275 /201701 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                                                                                                      | 14/09/2017 | 10/11/2017 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10275/201701. |
| IB/0037/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits | 13/10/2017 | n/a        |             |                                                                                                                                            |
| IAIN/0038/G         | This was an application for a group of variations.                                                                                                                                                                                                                                                                                       | 08/09/2017 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                             |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0036             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                               | 18/05/2017 | 10/11/2017 | Annex II and Labelling |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0034             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                | 26/04/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10275 /201607 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                                                                                                                                                                                                                          | 09/02/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0033             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                      | 16/12/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0032             | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                   | 16/12/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0031/G           | This was an application for a group of variations. II: C.I.4 Update of section 4.8 of the SmPC with data on exposure and section 5.1 of the SmPC with information on maintenance of long-term efficacy based on clinical study data (study ATTAIN) II: C.I.4 Update of section 4.8 of the SmPC in order to add information concerning the onset and duration of flu-like symptoms based on clinical study data (study ALLOW). The Package Leaflet is updated | 15/12/2016 | 10/11/2017 | SmPC and PL            | In view of the new emerging data from two clinical studies, the Product Information was updated with regards to efficacy, safety and tolerability of the product. The following revisions were introduced in section 4 of the Package Leaflet to add information on managing flu-like symptoms (new text bold, old text in strikethrough mode): Three simple ways to help reduce the impact of flu-like symptoms: |

<div style=\"page-break-after: always\"></div>

|                     | accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | 1. (Strikethrough text) Use your Plegridy injection just before bedtime. This may allow you to sleep through the effects. (To be replaced with the following text) Consider the timing of your Plegridy injection. The start and end of flu-like symptoms are different for every patient. On average, flu-like symptoms begin approximately 10 hours after injection and last between 12 and 24 hours. 2. Take paracetamol or ibuprofen half an hour before your Plegridy injection. (Strikethrough text) and continue taking it for up to a day. Speak to your doctor or pharmacist about (To be replaced with the following text) how much to take and how long to take it. (Strikethrough text) the right dose. 3. If you have a fever, drink plenty of water to keep you hydrated.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027             | Introduction of real-time release testing of the pre- filled pen presentations. B.II.d.3 - Variations related to the introduction of real-time release or parametric release in the manufacture of the finished product                            | 15/09/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0029             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                         | 12/09/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10275 /201601 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                | 02/09/2016 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| WS/0927             | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                               | 14/07/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                   |            |            |    |                    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|--------------------|
| N/0028  | Update of the package leaflet with revised contact details of the local representatives for Romania and Norway. In addition the MAH took the opportunity to make minor linguistic amendments to the French Labelling and Finnish package leaflet and instructions for use. Minor change in labelling or package leaflet not                                                                                                           | 30/06/2016 | 08/09/2016 | PL | connected with the |
| IB/0024 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                      | 05/04/2016 | n/a        |    |                    |
| N/0023  | Update of the Package Leaflet with revised contact details of the local representatives for Estonia and Latvia and formatting changes were made to the Package Leaflet in line with the user testing. In addition, the MAH took the opportunity to make minor linguistic amendments , formatting changes and alignments of texts to ensure consistency in the Labelling and Package Leaflets for: EN, CS, DE, ES, PT, RO, SL, and SE. | 11/02/2016 | 08/09/2016 | PL | FI, HR, IT,        |

<div style=\"page-break-after: always\"></div>

|                     | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10275 /201507 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                                                                                                                                                                                                                                              | 11/02/2016 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0022              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                 | 15/12/2015 | 08/09/2016 | PL                     |                                   |
| IB/0021             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                       | 13/11/2015 | n/a        |                        |                                   |
| WS/0805             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of SmPC section 4.8 and PL section 4 in order to include class text for interferon-beta products regarding pulmonary arterial hypertension (PAH). This change has been agreed by PRAC and endorsed by CHMP on 23 April 2015. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 29/10/2015 | 08/09/2016 | SmPC and PL            |                                   |
| WS/0806             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of SmPC, Labelling and Package Leaflet in line with EMA recommendation and QRD template. In addition, MAH took the opportunity to implement                                                                                                                                                                                 | 17/09/2015 | 08/09/2016 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | linguistic and editorial corrections. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                          |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/0615             | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                               | 11/09/2015 | n/a |                                   |
| PSUSA/10275 /201501 | Periodic Safety Update EU Single assessment - peginterferon beta-1A                                                                                                                                                                                           | 10/09/2015 | n/a | PRAC Recommendation - maintenance |
| IA/0017             | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                               | 07/08/2015 | n/a |                                   |
| WS/0750             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation | 06/08/2015 | n/a |                                   |
| IA/0016             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                  | 30/07/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0014/G   | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 28/07/2015   | n/a   |           |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IB/0012     | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 27/07/2015   | n/a   |           |
|             | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former | 01/07/2015   | n/a   | IA/0011/G |

<div style=\"page-break-after: always\"></div>

|           | with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material   |            |            |                 | non EU Pharmacopoeial   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------|
| IAIN/0010 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                    | 26/06/2015 | 08/09/2015 | Annex II and PL |                         |
| IB/0008/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation                                                                                                                                                                                                          | 23/06/2015 | n/a        |                 |                         |
| IG/0558/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                               | 12/05/2015 | n/a        |                 |                         |

<div style=\"page-break-after: always\"></div>

|           | change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                          |            |            |          | A.4 - Administrative   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------|
| II/0004/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other | 22/01/2015 | 08/09/2015 | Annex II | variation              |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/10/2014 | 08/09/2015 | PL       |                        |
|           | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.d.2.a - Change in test procedure for the finished                                                                                                                                                                                                                                                                                                              | 11/09/2014 | n/a        |          | IB/0001/G              |

<div style=\"page-break-after: always\"></div>

|           | - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                          |            |            |      | product procedure   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------|
| IB/0002   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                          | 09/09/2014 | 08/09/2015 | SmPC |                     |
| IB/0003/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation | 03/09/2014 | n/a        |      |                     |